Prevalence and Prognosis of Relapse of Nephroblastoma at the Pediatric Oncology Unit of Bamako

HTML  XML Download Download as PDF (Size: 286KB)  PP. 317-325  
DOI: 10.4236/ojped.2019.94031    579 Downloads   1,406 Views  

ABSTRACT

The nephroblastoma is the third pediatric cancer in Mali, this study aimed to describe the prevalence and prognosis of nephroblastoma relapses. Methods: It was a descriptive retrospective study over a 10-year period from January 2005 to March 2015. We collected children aged 0 to 15 years followed for relapse of nephroblastoma in the pediatric oncology unit of university hospital center (UHC) Gabriel Toure. Results: The frequency of relapse of nephroblastoma was 7.4% (19 cases) whose mean age was 42 months with a sex ratio of 1.3. The relapse occurred before the end of the postoperative course in 16% of cases (3 patients). It was local recurrence in 52% of cases (10 patients), pulmonary 16% (3 patients), and hepatic 11% (2 patients). According to the SIOP classification, 47% of patients were diagnosed in stage III (9 patients) and 21% (4 patients) in stage IV. The tumor was high risk in 37%. Palliative chemotherapy was performed in 63% of the patients (12 patients) and the remaining seven were put on a high risk diet. The overall survival at 5 years was 21% or 4 patients. Conclusion: Our results showed all the difficulties in the management of nephroblastoma relapses in our context.

Share and Cite:

Diakité, F. , Togo, P. , Doumbia, A. , Traoré, F. , Traoré, M. , Sacko, K. , Coulibaly, C. , Traoré, N. , Touré, A. , Maiga, B. , Sidibé, L. , Konaté, D. , Diall, A. , Dembélé, A. , Coulibaly, C. , Traoré, C. and Togo, B. (2019) Prevalence and Prognosis of Relapse of Nephroblastoma at the Pediatric Oncology Unit of Bamako. Open Journal of Pediatrics, 9, 317-325. doi: 10.4236/ojped.2019.94031.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.